New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...

The School of Psychology at the University of Southampton is seeking to make a strategic appointment of a part time permanent 0.4 FTE post to support education and training, and more specifically ...

At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...

ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from ...

Investing.com - Barclays has maintained its Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a price target of $44.00, representing nearly 79% upside from the current price of $24.61.

Greetings and welcome to PolyPid's Fourth Quarter and Full Year 2025 Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for ...

In today’s digital world, audio content has become a crucial element of communication, learning, and entertainment. Podcasts, video narrations, online courses, and voice assistants all rely on voice ...

PolyPid reported a quarterly loss of $0.41 per share for Q4 2025, falling short of the expected loss of $0.33 per share. This resulted in a negative surprise of 24.24%, reflecting challenges in the ...

Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...

New York, New York--(Newsfile Corp. - February 2, 2026) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it ...